Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience
This study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and...
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2018-08, Vol.93 (8), p.1074-1081 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1081 |
|---|---|
| container_issue | 8 |
| container_start_page | 1074 |
| container_title | American journal of hematology |
| container_volume | 93 |
| creator | Ganzel, Chezi Sun, Zhuoxin Cripe, Larry D. Fernandez, Hugo F. Douer, Dan Rowe, Jacob M. Paietta, Elisabeth M. Ketterling, Rhett O'Connell, Michael J. Wiernik, Peter H. Bennett, John M. Litzow, Mark R. Luger, Selina M. Lazarus, Hillard M. Tallman, Martin S. |
| description | This study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long‐term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow‐up was 9.7 years. The median OS from relapse was 0.5 years and the 5‐year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century. |
| doi_str_mv | 10.1002/ajh.25162 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6699929</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2056400632</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5092-ed4d236d2bcb6e6cc30c09fbcbfbeb7c614daa81b4466120bec33b3c5a66663d3</originalsourceid><addsrcrecordid>eNp1kc1u1DAURi0EokPLghdAltjAYtprO_HELJBGo_5qaCVU2FqOc9PxKImDnQydHY_AM_IkuExbARLe2NY9Pvqsj5BXDA4ZAD8y69Uhz5nkT8iEgZLTQub8KZmAkCydQe2RFzGuARjLCnhO9rhSkIuZmpDxC4Yt7b0PtPHdzc_vPwYMLY1j2LiNaajraG_iQE1X0dYHpAEtdgONw1g5jLRODwM2po9Y0fnHZaIHl4D4nl6vkB4vrk6Tc774dH5J8bbHkIYWD8iz2jQRX97v--TzyfH14my6vDo9X8yXU5uD4lOssooLWfHSlhKltQIsqDrd6hLLmZUsq4wpWJllUjIOJVohSmFzI9MSldgnH3befixbrO6SB9PoPrjWhK32xum_J51b6Ru_0VIqpbhKgrf3guC_jhgH3bposWlMh36MmkMuMwApeELf_IOu_Ri69L1EFcUsl_msSNS7HWWDjzFg_RiGgb4rU6cy9e8yE_v6z_SP5EN7CTjaAd9cg9v_m_T84myn_AUiXaww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2088756578</pqid></control><display><type>article</type><title>Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience</title><source>Wiley-Blackwell Journals</source><source>Wiley Free Archive</source><source>EZB Electronic Journals Library</source><creator>Ganzel, Chezi ; Sun, Zhuoxin ; Cripe, Larry D. ; Fernandez, Hugo F. ; Douer, Dan ; Rowe, Jacob M. ; Paietta, Elisabeth M. ; Ketterling, Rhett ; O'Connell, Michael J. ; Wiernik, Peter H. ; Bennett, John M. ; Litzow, Mark R. ; Luger, Selina M. ; Lazarus, Hillard M. ; Tallman, Martin S.</creator><creatorcontrib>Ganzel, Chezi ; Sun, Zhuoxin ; Cripe, Larry D. ; Fernandez, Hugo F. ; Douer, Dan ; Rowe, Jacob M. ; Paietta, Elisabeth M. ; Ketterling, Rhett ; O'Connell, Michael J. ; Wiernik, Peter H. ; Bennett, John M. ; Litzow, Mark R. ; Luger, Selina M. ; Lazarus, Hillard M. ; Tallman, Martin S.</creatorcontrib><description>This study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long‐term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow‐up was 9.7 years. The median OS from relapse was 0.5 years and the 5‐year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.</description><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.25162</identifier><identifier>PMID: 29905379</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Clinical trials ; Cytogenetics ; Hematology ; Medical prognosis ; Survival ; Transplantation</subject><ispartof>American journal of hematology, 2018-08, Vol.93 (8), p.1074-1081</ispartof><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5092-ed4d236d2bcb6e6cc30c09fbcbfbeb7c614daa81b4466120bec33b3c5a66663d3</citedby><cites>FETCH-LOGICAL-c5092-ed4d236d2bcb6e6cc30c09fbcbfbeb7c614daa81b4466120bec33b3c5a66663d3</cites><orcidid>0000-0002-1722-4807</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.25162$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.25162$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29905379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ganzel, Chezi</creatorcontrib><creatorcontrib>Sun, Zhuoxin</creatorcontrib><creatorcontrib>Cripe, Larry D.</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Douer, Dan</creatorcontrib><creatorcontrib>Rowe, Jacob M.</creatorcontrib><creatorcontrib>Paietta, Elisabeth M.</creatorcontrib><creatorcontrib>Ketterling, Rhett</creatorcontrib><creatorcontrib>O'Connell, Michael J.</creatorcontrib><creatorcontrib>Wiernik, Peter H.</creatorcontrib><creatorcontrib>Bennett, John M.</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><creatorcontrib>Luger, Selina M.</creatorcontrib><creatorcontrib>Lazarus, Hillard M.</creatorcontrib><creatorcontrib>Tallman, Martin S.</creatorcontrib><title>Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><description>This study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long‐term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow‐up was 9.7 years. The median OS from relapse was 0.5 years and the 5‐year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.</description><subject>Clinical trials</subject><subject>Cytogenetics</subject><subject>Hematology</subject><subject>Medical prognosis</subject><subject>Survival</subject><subject>Transplantation</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1kc1u1DAURi0EokPLghdAltjAYtprO_HELJBGo_5qaCVU2FqOc9PxKImDnQydHY_AM_IkuExbARLe2NY9Pvqsj5BXDA4ZAD8y69Uhz5nkT8iEgZLTQub8KZmAkCydQe2RFzGuARjLCnhO9rhSkIuZmpDxC4Yt7b0PtPHdzc_vPwYMLY1j2LiNaajraG_iQE1X0dYHpAEtdgONw1g5jLRODwM2po9Y0fnHZaIHl4D4nl6vkB4vrk6Tc774dH5J8bbHkIYWD8iz2jQRX97v--TzyfH14my6vDo9X8yXU5uD4lOssooLWfHSlhKltQIsqDrd6hLLmZUsq4wpWJllUjIOJVohSmFzI9MSldgnH3befixbrO6SB9PoPrjWhK32xum_J51b6Ru_0VIqpbhKgrf3guC_jhgH3bposWlMh36MmkMuMwApeELf_IOu_Ri69L1EFcUsl_msSNS7HWWDjzFg_RiGgb4rU6cy9e8yE_v6z_SP5EN7CTjaAd9cg9v_m_T84myn_AUiXaww</recordid><startdate>201808</startdate><enddate>201808</enddate><creator>Ganzel, Chezi</creator><creator>Sun, Zhuoxin</creator><creator>Cripe, Larry D.</creator><creator>Fernandez, Hugo F.</creator><creator>Douer, Dan</creator><creator>Rowe, Jacob M.</creator><creator>Paietta, Elisabeth M.</creator><creator>Ketterling, Rhett</creator><creator>O'Connell, Michael J.</creator><creator>Wiernik, Peter H.</creator><creator>Bennett, John M.</creator><creator>Litzow, Mark R.</creator><creator>Luger, Selina M.</creator><creator>Lazarus, Hillard M.</creator><creator>Tallman, Martin S.</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1722-4807</orcidid></search><sort><creationdate>201808</creationdate><title>Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience</title><author>Ganzel, Chezi ; Sun, Zhuoxin ; Cripe, Larry D. ; Fernandez, Hugo F. ; Douer, Dan ; Rowe, Jacob M. ; Paietta, Elisabeth M. ; Ketterling, Rhett ; O'Connell, Michael J. ; Wiernik, Peter H. ; Bennett, John M. ; Litzow, Mark R. ; Luger, Selina M. ; Lazarus, Hillard M. ; Tallman, Martin S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5092-ed4d236d2bcb6e6cc30c09fbcbfbeb7c614daa81b4466120bec33b3c5a66663d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical trials</topic><topic>Cytogenetics</topic><topic>Hematology</topic><topic>Medical prognosis</topic><topic>Survival</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ganzel, Chezi</creatorcontrib><creatorcontrib>Sun, Zhuoxin</creatorcontrib><creatorcontrib>Cripe, Larry D.</creatorcontrib><creatorcontrib>Fernandez, Hugo F.</creatorcontrib><creatorcontrib>Douer, Dan</creatorcontrib><creatorcontrib>Rowe, Jacob M.</creatorcontrib><creatorcontrib>Paietta, Elisabeth M.</creatorcontrib><creatorcontrib>Ketterling, Rhett</creatorcontrib><creatorcontrib>O'Connell, Michael J.</creatorcontrib><creatorcontrib>Wiernik, Peter H.</creatorcontrib><creatorcontrib>Bennett, John M.</creatorcontrib><creatorcontrib>Litzow, Mark R.</creatorcontrib><creatorcontrib>Luger, Selina M.</creatorcontrib><creatorcontrib>Lazarus, Hillard M.</creatorcontrib><creatorcontrib>Tallman, Martin S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ganzel, Chezi</au><au>Sun, Zhuoxin</au><au>Cripe, Larry D.</au><au>Fernandez, Hugo F.</au><au>Douer, Dan</au><au>Rowe, Jacob M.</au><au>Paietta, Elisabeth M.</au><au>Ketterling, Rhett</au><au>O'Connell, Michael J.</au><au>Wiernik, Peter H.</au><au>Bennett, John M.</au><au>Litzow, Mark R.</au><au>Luger, Selina M.</au><au>Lazarus, Hillard M.</au><au>Tallman, Martin S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2018-08</date><risdate>2018</risdate><volume>93</volume><issue>8</issue><spage>1074</spage><epage>1081</epage><pages>1074-1081</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><abstract>This study examines the long‐term OS of relapsed AML patients who were enrolled to 9 successive ECOG‐ACRIN trials for newly diagnosed AML, during 1984‐2008. The objectives were to examine whether there is a trend of improvement in the survival of relapsed AML patients in the more recent studies and to search for prognostic factors that are associated with long‐term OS after relapse. A total of 3012 patients were enrolled, 1779 (59.1%) achieved CR1 and of these, 58.9% relapsed. The median follow‐up was 9.7 years. The median OS from relapse was 0.5 years and the 5‐year OS was 10 (±1)%. These results were similar even for the most recent studies. A multivariate model showed that age, cytogenetics at diagnosis, duration of CR1 and undergoing allogeneic transplantation were significantly associated with OS from relapse. Even among patients who relapsed with better prognostic factors; age < 40 and CR1 > 12 months, there was no significant OS difference between the studies. In conclusion, this large cohort appears to confirm that the survival of AML patients postrelapse continues to be dismal and has not improved during the past quarter of a century.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29905379</pmid><doi>10.1002/ajh.25162</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1722-4807</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2018-08, Vol.93 (8), p.1074-1081 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6699929 |
| source | Wiley-Blackwell Journals; Wiley Free Archive; EZB Electronic Journals Library |
| subjects | Clinical trials Cytogenetics Hematology Medical prognosis Survival Transplantation |
| title | Very poor long‐term survival in past and more recent studies for relapsed AML patients: The ECOG‐ACRIN experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A10%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Very%20poor%20long%E2%80%90term%20survival%20in%20past%20and%20more%20recent%20studies%20for%20relapsed%20AML%20patients:%20The%20ECOG%E2%80%90ACRIN%20experience&rft.jtitle=American%20journal%20of%20hematology&rft.au=Ganzel,%20Chezi&rft.date=2018-08&rft.volume=93&rft.issue=8&rft.spage=1074&rft.epage=1081&rft.pages=1074-1081&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.25162&rft_dat=%3Cproquest_pubme%3E2056400632%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2088756578&rft_id=info:pmid/29905379&rfr_iscdi=true |